Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289122 | 1.00 | GYS1 (0.49) | GYS1KMT2AHCRTR1HCRTR2TDP1 | |
| SCHEMBL28020910 | 0.90 | HCRTR1 (0.45) | GYS1KMT2AHCRTR1HCRTR2TDP1 | |
| SCHEMBL288451 | 0.87 | GYS1 (0.58) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL1612182 | 0.87 | GYS1 (0.58) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL16600994 | 0.86 | KMT2A (0.55) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL10377856 | 0.86 | KMT2A (0.55) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL288266 | 0.80 | P2RX7 (0.48) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL288267 | 0.80 | P2RX7 (0.48) | GYS1KMT2AHCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL19177602 | 0.78 | ALDH1A1 (0.50) | GYS1KMT2AHCRTR1HCRTR2TDP1 | |
| SCHEMBL19177604 | 0.78 | ALDH1A1 (0.50) | GYS1KMT2AHCRTR1HCRTR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | disclosed |
| EP-2427429-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| WO-2010128102-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | GYS1 1486/4885KMT2A 1409/4885HCRTR1 169/4885 |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | GYS1 1486/4885KMT2A 1409/4885HCRTR1 169/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | GYS1 1486/4885KMT2A 1409/4885HCRTR1 169/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | GYS1 1486/4885KMT2A 1409/4885HCRTR1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.